R13921CP: NCD 210.3 Screening for Colorectal Cancer-Non-Invasive Biomarker Tests
CMS determined that, effective June 8, 2026, non-invasive biomarker colorectal cancer screening tests are covered for Medicare beneficiaries under NCD 210.3 when they meet specific criteria. Covered tests are limited to once every three years for asymptomatic, average-risk patients aged 45 to 85, and the test must be FDA market authorized and indicated for colorectal cancer screening, processed in a CLIA certified laboratory, and meet defined sensitivity and specificity thresholds. The transmittal adds ColoSense (0421U) as a covered screening test and sets an implementation date of January 4, 2027 for the claims processing changes.